Book chapter
Activation of NK Cell Responses and Immunotherapy of Cancer
Advances in Tumor Immunology and Immunotherapy, pp.57-66
Current Cancer Research, Springer Nature
01/01/2014
DOI: 10.1007/978-1-4614-8809-5_4
Abstract
Monoclonal antibodies, including rituximab, are a mainstay in the therapy of cancer; however, there is much we do not understand about their mechanisms of action. In vitro analysis, animal models, and clinical trials suggest signaling, complement, and cellular cytotoxicity, each playing a role. Increasing evidence indicates that these mechanisms of action do not operate in isolation and that there are considerable interactions, some synergistic and some antagonistic, between mechanisms that can impact on the efficacy of therapy. An improved understanding of the relative importance of each mechanism, and how these mechanisms interact in various clinical scenarios, is vital if we are to make a highly valuable approach to cancer therapy even better.
Details
- Title: Subtitle
- Activation of NK Cell Responses and Immunotherapy of Cancer
- Creators
- George J. Weiner - University of Iowa
- Contributors
- J D Rosenblatt (Editor)E R Podack (Editor)G N Barber (Editor)A Ochoa (Editor)
- Resource Type
- Book chapter
- Publication Details
- Advances in Tumor Immunology and Immunotherapy, pp.57-66
- Publisher
- Springer Nature; NEW YORK
- Series
- Current Cancer Research
- DOI
- 10.1007/978-1-4614-8809-5_4
- ISSN
- 0940-0745
- Number of pages
- 10
- Language
- English
- Date published
- 01/01/2014
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984359899802771
Metrics
8 Record Views